The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia

Published:2015-05-07 Issue:19 Volume:125 Page:2915-2922
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Brown Jennifer R.¹,Barrientos Jacqueline C.²,Barr Paul M.³,Flinn Ian W.⁴,Burger Jan A.⁵,Tran Anh⁶,Clow Fong⁶,James Danelle F.⁶,Graef Thorsten⁶,Friedberg Jonathan W.³,Rai Kanti²,O’Brien Susan⁵

Affiliation:

1. Dana-Farber Cancer Institute, Boston, MA;

2. Hofstra North Shore–Long Island Jewish Medical Center School of Medicine at Hofstra University, Hempstead, NY;

3. Hematology/Oncology Division, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY;

4. Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN;

5. The University of Texas MD Anderson Cancer Center, Houston, TX; and

6. Pharmacyclics, Sunnyvale, CA

Abstract

Key Points Ibrutinib was well tolerated when administered with BR CIT in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Ibrutinib added to CIT was associated with a high degree of clinical activity that compares favorably to historical reports of CIT alone.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/19/2915/1384731/2915.pdf

Reference42 articles.

1. Update on therapy of chronic lymphocytic leukemia.;Gribben;J Clin Oncol,2011

2. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.;Rai;N Engl J Med,2000

3. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.;Catovsky;Lancet,2007

4. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.;Eichhorst;Blood,2006

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NIR‐Actuated Targeted Janus Nanomotors Remodel Immunosuppressive Tumor Microenvironment for Augmented Cancer Immunotherapy;Advanced Healthcare Materials;2023-10-27

2. Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia;Cells;2022-10-19

3. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies;Journal of Hematology & Oncology;2022-10-01

4. Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer;World Journal of Clinical Cases;2022-09-26

5. Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance;Blood and Lymphatic Cancer: Targets and Therapy;2022-07